Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0000912282-15-000398
Filing Date
2015-10-28
Accepted
2015-10-28 14:58:22
Documents
10
Period of Report
2015-09-25

Document Format Files

Seq Description Document Type Size
1 oncolytics6k_10282015.htm 6-K 22571
2 UNDERTAKING TO THE EXECUTIVE DIRECTOR DATED 20150925 ex99_1.htm EX-99.1 7897
3 undertaking_p1.jpg GRAPHIC 260363
4 undertaking_p2.jpg GRAPHIC 316306
5 undertaking_p3.jpg GRAPHIC 246609
6 undertaking_p4.jpg GRAPHIC 258078
7 undertaking_p5.jpg GRAPHIC 225298
8 undertaking_p7.jpg GRAPHIC 229376
9 undertaking_p8.jpg GRAPHIC 169923
10 undertakingp_6.jpg GRAPHIC 255447
  Complete submission text file 0000912282-15-000398.txt   2733971
Mailing Address 210 - 1167 KENSINGTON CRES NW CALGARY A0 T2N 1X7
Business Address 1167 KENSINGTON CRES NW SUITE 210 CALGARY ALBERTA CANADA T2N 1X7 ALBERTA CANADA A0 00000 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 000-31062 | Film No.: 151180015
SIC: 2834 Pharmaceutical Preparations